CRISPR

CRISPR1-dre-mir-24-4

ID

ZDB-CRISPR-170626-5

Previous Names

CRISPR1-mir24-4

Target

dre-mir-24-4 (1)

Sequence

5' - CCAGTTTAGCAGGCACAAGT - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
ya327	dre-mir-24-4

Expression

Gene expression in Wild Types + CRISPR1-dre-mir-24-4

No data available

Phenotype

Phenotype resulting from CRISPR1-dre-mir-24-4

No data available

Phenotype of all Fish created by or utilizing CRISPR1-dre-mir-24-4

Phenotype	Fish	Conditions	Figures
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; la116Tg	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 6 from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal	dre-mir-24-4^ya327/ya327; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal	dre-mir-24-4^ya327/ya327; mir24-1^ya324/ya324; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-1^ya324/ya324; la116Tg	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 6 from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal	dre-mir-24-4^ya327/ya327; mir24-2^ya325/ya325; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-2^ya325/ya325; la116Tg	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 6 from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; la116Tg	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 6 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-1^ya324/ya324; mir24-2^ya325/ya325; la116Tg	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 6 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-1^ya324/ya324; mir24-2^ya325/ya325; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal	dre-mir-24-4^ya327/ya327; mir24-1^ya324/ya324; mir24-2^ya325/ya325; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-1^ya324/ya324; la116Tg	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 6 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-1^ya324/ya324; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-1^ya324/ya324; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-2^ya325/ya325; la116Tg	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 6 from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-2^ya325/ya325; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-2^ya325/ya325; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-1^ya324/ya324; mir24-2^ya325/ya325; la116Tg	chemical treatment by environment: 6-bromoindirubin-3'-oxime	Fig. 6 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-1^ya324/ya324; mir24-2^ya325/ya325; la116Tg	chemical treatment by environment: EC 3.4.23.46 (memapsin 2) inhibitor	Fig. 6 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-1^ya324/ya324; mir24-2^ya325/ya325; la116Tg	hypoxia	Fig. 6 from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-1^ya324/ya324; mir24-2^ya325/ya325; la116Tg	control	Fig. 4 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-1^ya324/ya324; mir24-2^ya325/ya325; la116Tg	chemical treatment by environment: semaxanib	Fig. 6 from Kasper et al., 2017
hypobranchial artery decreased length, abnormal	dre-mir-24-4^ya327/ya327; mir24-3^ya326/ya326; mir24-1^ya324/ya324; mir24-2^ya325/ya325; la116Tg	control	Fig. 4 from Kasper et al., 2017

Citations